Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Targeting Mitogen-Activated Protein Kinase Interacting Kinases (MNK1 and MNK2) is a key strategy in cancer therapy.
• Existing MNK inhibitors primarily use an adenosine triphosphate (ATP)-competitive mode, limiting exploration of alternative binding mechanisms.

Purpose of the Study:

• To identify and validate a novel scaffold for MNK inhibitors.
• To characterize the mechanism of action of a new class of MNK inhibitors.
• To explore a non-ATP-competitive binding mode for MNK inhibition.

Main Methods:

• Rational drug design to identify novel MNK inhibitor scaffolds.
• Signaling pathway analysis to confirm target engagement.
• Molecular modeling to elucidate the binding mode of the identified inhibitor.

Main Results:

• The 4,6-diaryl-pyrazolo[3,4-b]pyridin-3-amine scaffold was identified as a core for MNK inhibitors.
• The hit compound EB1 demonstrated specific inhibition of tumor cell growth, sparing normal cells.
• Molecular modeling revealed EB1 binds to an inactive MNK1 conformation, interacting with the DFD motif, distinct from ATP-competitive inhibitors.

Conclusions:

• EB1 represents a novel, non-ATP-competitive inhibitor of MNK1 and MNK2.
• This unique binding mode avoids paradoxical kinase activation, offering a potential advantage over existing therapies.
• EB1 provides a promising foundation for developing a new generation of oncology drugs targeting MNKs.